Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-tumour necrosis factor therapy in Crohn's disease: where are we now?

× No keyword cloud information.

10 in total

1. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance.

Authors: K Ina; J Itoh; K Fukushima; K Kusugami; T Yamaguchi; K Kyokane; A Imada; D G Binion; A Musso; G A West; G M Dobrea; T S McCormick; E G Lapetina; A D Levine; C A Ottaway; C Fiocchi
Journal: J Immunol Date: 1999-07-15 Impact factor: 5.422

2. Infliximab for the treatment of fistulas in patients with Crohn's disease.

Authors: D H Present; P Rutgeerts; S Targan; S B Hanauer; L Mayer; R A van Hogezand; D K Podolsky; B E Sands; T Braakman; K L DeWoody; T F Schaible; S J van Deventer
Journal: N Engl J Med Date: 1999-05-06 Impact factor: 91.245

3. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

Authors: M Boers; A C Verhoeven; H M Markusse; M A van de Laar; R Westhovens; J C van Denderen; D van Zeben; B A Dijkmans; A J Peeters; P Jacobs; H R van den Brink; H J Schouten; D M van der Heijde; A Boonen; S van der Linden
Journal: Lancet Date: 1997-08-02 Impact factor: 79.321

4. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors: S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal: N Engl J Med Date: 1997-10-09 Impact factor: 91.245

5. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.

Authors: W A Stack; S D Mann; A J Roy; P Heath; M Sopwith; J Freeman; G Holmes; R Long; A Forbes; M A Kamm
Journal: Lancet Date: 1997-02-22 Impact factor: 79.321

6. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.

Authors: W J Sandborn; B G Feagan; S B Hanauer; D H Present; L R Sutherland; M A Kamm; D C Wolf; J P Baker; C Hawkey; A Archambault; C N Bernstein; C Novak; P K Heath; S R Targan
Journal: Gastroenterology Date: 2001-05 Impact factor: 22.682

7. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors: J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal: N Engl J Med Date: 2001-10-11 Impact factor: 91.245

8. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

Authors: T ten Hove; C van Montfrans; M P Peppelenbosch; S J H van Deventer
Journal: Gut Date: 2002-02 Impact factor: 23.059

9. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway.

Authors: A Lügering; M Schmidt; N Lügering; H G Pauels; W Domschke; T Kucharzik
Journal: Gastroenterology Date: 2001-11 Impact factor: 22.682

10. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection.

Authors: V Kindler; A P Sappino; G E Grau; P F Piguet; P Vassalli
Journal: Cell Date: 1989-03-10 Impact factor: 41.582

10 in total

2 in total

1. The long-term outcome of anti-TNF alpha therapy in perianal Crohn's disease.

Authors: J Rayen; T Currie; R B Gearry; F Frizelle; T Eglinton
Journal: Tech Coloproctol Date: 2017-01-09 Impact factor: 3.781

2. Modulation of Intestinal Epithelial Permeability by Plasma from Patients with Crohn's Disease in a Three-dimensional Cell Culture Model.

Authors: Pan Xu; Elhaseen Elamin; Montserrat Elizalde; Paul P H A Bours; Marieke J Pierik; Ad A M Masclee; Daisy M A E Jonkers
Journal: Sci Rep Date: 2019-02-14 Impact factor: 4.379

2 in total